Suppr超能文献

癌症细胞治疗的新方向:癌症细胞治疗峰会综述

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.

作者信息

Stroncek David F, Berger Carolina, Cheever Martin A, Childs Richard W, Dudley Mark E, Flynn Peter, Gattinoni Luca, Heath James R, Kalos Michael, Marincola Francesco M, Miller Jeffrey S, Mostoslavsky Gustavo, Powell Daniel J, Rao Mahendra, Restifo Nicholas P, Rosenberg Steven A, O'Shea John, Melief Cornelis J M

机构信息

Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA.

出版信息

J Transl Med. 2012 Mar 15;10:48. doi: 10.1186/1479-5876-10-48.

Abstract

A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.

摘要

一场关于癌症细胞疗法的峰会讨论并展示了与过继性细胞疗法用于黑色素瘤及其他癌症相关的进展。该峰会表明这一领域正在迅速发展。传统的细胞疗法,如肿瘤浸润淋巴细胞(TIL),正变得更有效且更易获得。基因疗法正成为过继性细胞疗法中的一项重要工具。淋巴细胞经过改造后可表达高亲和力T细胞受体(TCR)、嵌合抗体-T细胞受体(CAR)和细胞因子。在临床前模型中已表明,具有更多初始和干细胞样特征的T细胞亚群比未筛选的群体更有效,现在有可能对T细胞进行重编程并产生具有干细胞特征的T细胞。未来,可以设想将T细胞的过继转移与针对同源抗原的特异性疫苗接种相结合,以进一步提高这些疗法的有效性。

相似文献

2
Adoptive CD8 T cell therapy against cancer:Challenges and opportunities.
Cancer Lett. 2019 Oct 10;462:23-32. doi: 10.1016/j.canlet.2019.07.017. Epub 2019 Jul 26.
3
[Application of gene therapy in tumor adoptive immunotherapy].
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008 Apr;25(2):482-6.
6
Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
Crit Rev Oncol Hematol. 2019 Apr;136:1-12. doi: 10.1016/j.critrevonc.2019.01.015. Epub 2019 Jan 25.
7
Principles of adoptive T cell therapy in cancer.
Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5.
8
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Clin Cancer Res. 2011 Apr 1;17(7):1664-73. doi: 10.1158/1078-0432.CCR-10-2272. Epub 2011 Feb 15.
9
Adoptive T-cell transfer in melanoma.
Immunotherapy. 2013 Jan;5(1):79-90. doi: 10.2217/imt.12.143.
10
Tumor-infiltrating lymphocytes in melanoma.
Curr Oncol Rep. 2012 Oct;14(5):468-74. doi: 10.1007/s11912-012-0257-5.

引用本文的文献

2
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.
Mol Cancer. 2023 Nov 28;22(1):189. doi: 10.1186/s12943-023-01873-0.
3
Adding recombinant AAVs to the cancer therapeutics mix.
Mol Ther Oncolytics. 2022 Oct 2;27:73-88. doi: 10.1016/j.omto.2022.09.009. eCollection 2022 Dec 15.
4
An overview of multiplexed analyses of CAR T-cell therapies: insights and potential.
Expert Rev Proteomics. 2021 Sep;18(9):767-780. doi: 10.1080/14789450.2021.1992276. Epub 2021 Oct 17.
5
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Crit Rev Immunol. 2019;39(2):105-122. doi: 10.1615/CritRevImmunol.2019030788.
6
Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood.
Cell Rep. 2019 Sep 3;28(10):2728-2738.e7. doi: 10.1016/j.celrep.2019.07.106.
8
Cellular Therapies in Systemic Sclerosis: Recent Progress.
Curr Rheumatol Rep. 2016 Feb;18(2):12. doi: 10.1007/s11926-015-0555-7.
9
Single-cell analysis tools for drug discovery and development.
Nat Rev Drug Discov. 2016 Mar;15(3):204-16. doi: 10.1038/nrd.2015.16. Epub 2015 Dec 16.
10
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
J Immunol Res. 2015;2015:191832. doi: 10.1155/2015/191832. Epub 2015 Jul 7.

本文引用的文献

2
Th17 cells are long lived and retain a stem cell-like molecular signature.
Immunity. 2011 Dec 23;35(6):972-85. doi: 10.1016/j.immuni.2011.09.019. Epub 2011 Dec 15.
5
A human memory T cell subset with stem cell-like properties.
Nat Med. 2011 Sep 18;17(10):1290-7. doi: 10.1038/nm.2446.
6
Biomarkers in T cell therapy clinical trials.
J Transl Med. 2011 Aug 19;9:138. doi: 10.1186/1479-5876-9-138.
8
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10.
10
Treating cancer with genetically engineered T cells.
Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验